WEBINAR: Enabling timely comparative effectiveness research: head-to-head analysis of GLP-1s for weight loss – VIEW ON DEMAND
Enabling timely comparative effectiveness research: head-to-head analysis of GLP-1s for weight loss
View now on demand
This webinar will highlight results of a real-world GLP-1 comparative effectiveness study and the impact of timely and representative RWD in assessing performance of new therapies.
GLP-1 drugs have garnered extensive media coverage and celebrity endorsements over the past year for their ability to drive weight loss. With more than 73% of adults in the US considered overweight or obese, millions taking GLP-1s, and head-to-head randomized clinical trials still being more than a year away, understanding the real-world effectiveness of these drugs is crucial. Truveta Research recently conducted a ground-breaking comparative effectiveness study using timely real-world data.
Speakers
Tricia Rodriguez, PhD, MPH
Principal Applied Scientist, Truveta
Tricia Rodriguez, Principal Applied Scientist at Truveta, specializes in using real-world data (RWD) to study patient outcomes. With over a decade of experience in RWD, she’s conducted research and published in a variety of disease areas, including diabetes, colorectal cancer, cystic fibrosis, HIV, and eating disorders. Tricia holds a PhD in Health Economics and Outcomes Research and a Master’s in Public Health, both from the University of Washington. Before Truveta, she held research positions at Verily Life Sciences and the University of Washington.
Michael Simonov, MD
Chief Medical Officer and VP of Product Management, Truveta
Michael Simonov, MD, Chief Medical Officer and VP of Product Management at Truveta, is an internist and clinical informaticist who’s primary career focus has been leveraging electronic health record data for improving human health. At Truveta, he leads the product and clinical informatics teams to ensure Truveta Data and Studio provide highest-quality data to fuel clinical research. Prior to this role, he served as medical information officer for research at the Yale New Haven Health System and a clinical and EHR researcher in the Yale Department of Medicine.
What will you learn?
- Learn how type 2 diabetes-labeled semaglutide (Ozempic) and tirzepatide (Mounjaro) stack up in terms of weight loss potential in real-world settings
- Explore the role of RWE in gauging real-world effectiveness of pharmaceuticals, particularly in populations underrepresented in clinical trials
- Discover the power of timely and representative RWD to drive product innovation and accelerate medical breakthroughs
In association with
For more info on Truveta, please visit truveta.com and follow on LinkedIn here.
If you are interested in partnering with The Evidence Base for future webinars, please contact [email protected].